Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line
Background: Metastatic colorectal cancer (mCRC) constitutes one of the fatal worldwide neoplasms. Despite different modalities utilized in treatment, some patients progressed, raising the search for new predictive and prognostic markers. Vitamin D receptor (VDR) has different expression degrees in m...
Main Authors: | Salah Mabrook Khallaf, Amany Mohamed Abdel-Moatmed*, Shimaa Hassan Shabaan, Amen Hamdy Zaky, Ashraf Zeidan Abdalla |
---|---|
Format: | Article |
Language: | English |
Published: |
South Valley University, Faculty of Medicine
2024-01-01
|
Series: | SVU - International Journal of Medical Sciences |
Subjects: | |
Online Access: | https://svuijm.journals.ekb.eg/article_332709.html |
Similar Items
-
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
by: Yuankai Shi, et al.
Published: (2019-05-01) -
IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2008-09-01) -
Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
by: Ko AH
Published: (2016-03-01) -
Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide
by: Hakan Gelincik, et al.
Published: (2016-12-01) -
BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)